OpenAI introduces expanded capabilities of the GPT-Rosalind model series in the life sciences

OpenAI announced new capabilities for the GPT-Rosalind model series, which combines GPT-5.5’s agentic coding and tool-use features with scalable intelligence for life-sciences research. The development aims to accelerate drug discovery, analysis, design, and experimental workflows in enterprise environments.